Burjeel Medical City partners with TII for cancer treatment

The two-year collaboration will focus on engineering T-cell-based therapeutics and TIL therapy.

Burjeel Medical City (BMC) in Abu Dhabi has partnered with the Technology Innovation Institute (TII) to advance immunotherapy solutions for cancer treatment.

The two-year collaboration will focus on engineering T-cell-based therapeutics, including Chimeric Antigen Receptor T (CAR-T) cell therapy, and Tumor-Infiltrating Lymphocyte (TIL) therapy to help boost the body's immune system against cancer.

BMC will leverage technologies from TII, including its computational framework to identify patient-specific antigens relevant to the disease and develop personalised therapies. 

ALSO READ: Abu Dhabi to launch new AI academy for health workforce boost

“We live in times where cancers continue to proliferate with a ruthless and growing frequency, impacting the lives of those affected and their families,” Dr. Khaled Musallam, Chief Research Officer of Burjeel Holdings, said.

“Creating partnerships that help supercharge cancer research and treatment are crucial to enhance the pace of discoveries and improve patient outcomes,” Musallam added.